As of June 2025, the branded version of liraglutide, Saxenda, generated $165 million in annual sales alone, and the market for GLP-1s could be set to hit over $126 billion in sales by 2029
Portion-conscious products, high-protein snacks, ready-to-eat meals, hydration aids, functional beverages, mood-based offerings, and personalized shopping tools are all gaining traction among GLP-1 consumers
Most other GHS-receptor-active compounds in the broader research literature lack one or both of these properties
Myricetin and Dopamine - the Craving Addiction Pathways The QuickTake 30-second answer Want the science
From ensuring equitable access to addressing ethical concerns around longevity, the implications of such a drug extend far beyond individual patient care